NewAmsterdam Pharma Company N.V. (NAMSW)
- Previous Close
9.67 - Open
8.72 - Bid --
- Ask --
- Day's Range
8.30 - 8.30 - 52 Week Range
5.45 - 16.75 - Volume
831 - Avg. Volume
3,220 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
www.newamsterdampharma.comRecent News: NAMSW
View More
Performance Overview: NAMSW
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAMSW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAMSW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.19%
Return on Equity (ttm)
-46.20%
Revenue (ttm)
45.56M
Net Income Avi to Common (ttm)
-241.6M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
834.19M
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
-43.39M